Seguridad y pureza gracias al circuito cerrado

Uno de los principales valores diferenciales del sistema MEISE es su proceso integral en circuito cerrado, que evita que la sangre entre en contacto con el aire ambiental durante toda la preparación. Este procedimiento reduce significativamente el riesgo de contaminación y garantiza un producto final de máxima pureza y seguridad biológica.

La utilización de tecnología avanzada en circuito cerrado supone un importante avance para los centros hospitalarios y laboratorios que buscan optimizar la elaboración de suero ocular bajo estándares de calidad más exigentes.

Esterilidad garantizada para el paciente

El sistema incorpora un filtro de 0,22 micras, diseñado para asegurar la esterilidad final del producto. Según la Dra. Trujillo, esta tecnología permite preservar la integridad de los componentes beneficiosos del suero, ofreciendo al paciente la tranquilidad de recibir un tratamiento elaborado bajo estándares avanzados de calidad y seguridad.

Gracias a este proceso controlado, el sistema MEISE contribuye a mejorar la fiabilidad y trazabilidad en la producción de gotas de suero ocular estériles, un aspecto clave en oftalmología avanzada.

De un proceso artesanal a una solución semiautomatizada

MEISE permite evolucionar desde métodos manuales hacia un modelo semiautomatizado, optimizando tiempos y aumentando la capacidad de producción. Esto se traduce en una mayor eficiencia hospitalaria, posibilidad de atender a más pacientes y una mejora en la seguridad del profesional sanitario, al reducir la exposición a aerosoles y salpicaduras.

La automatización parcial del proceso facilita además la estandarización de la preparación del producto, reduciendo variabilidades y mejorando la calidad final del tratamiento.

Suero autólogo y homólogo: misma seguridad, distintas indicaciones

La Dra. María del Monte Trujillo destaca que el suero autólogo continúa siendo la primera opción por su total biocompatibilidad: “el paciente es su propia medicina”. Sin embargo, el suero homólogo resulta fundamental cuando no es posible realizar extracciones repetidas o existen condiciones clínicas que lo impiden.

En ambos casos, el sistema MEISE garantiza los mismos estándares de filtración, esterilidad y calidad, proporcionando un entorno seguro para la preparación de tratamientos oftalmológicos personalizados.

Tecnología al servicio de la oftalmología avanzada

La incorporación de soluciones como MEISE, distribuida en España por Biogen Diagnóstica, representa un avance significativo en la producción de suero ocular, ofreciendo a hospitales y centros especializados una herramienta más segura, eficiente y alineada con las necesidades de la medicina actual.

En Biogen Diagnóstica seguimos comprometidos con acercar innovación y tecnología sanitaria de alto valor a los profesionales de la salud, impulsando soluciones que mejoran tanto los procesos clínicos como la seguridad de los pacientes.

Más información sobre el sistema MEISE

This was one of the central themes discussed during the 1st ECMO Update Conference in Spain. Held on 26 February at the Ramón y Cajal University Hospital in Madrid and organised by the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC), the event brought together national and international specialists to analyse the current situation of extracorporeal support in Spain and to share clinical, organisational and training experiences.

A highly complex therapy on the rise

ECMO is an extracorporeal life support technique that temporarily replaces the function of the heart and/or lungs through an external circuit that oxygenates the blood and returns it to the body. It is used in critical situations such as severe respiratory failure, cardiogenic shock or refractory cardiac arrest, when conventional treatments are no longer sufficient.

In Spain, the development of specialised intensive care medicine programmes focused on ECMO has progressed significantly. This growth, led by multidisciplinary teams, has made it possible to expand clinical indications and dramatically improve the care provided to critically ill patients.

The current challenge: organising the healthcare system

During the conference, several specialists highlighted that the expansion of ECMO programmes has not always been accompanied by coordinated regional planning. According to the experts, the current organisation varies between Spain’s autonomous communities, creating differences in coverage, coordination between centres and critical care patient transport models.

In response to this situation, professionals from SEMICYUC stressed the need to move towards a structured national strategy for adult ECMO support, with the aim of ensuring:

• Equal access to therapy throughout the country.
• Consistency in healthcare quality standards.
• Sustainability of the public healthcare system.

International models show that the creation of reference centres, clearly defined referral networks and specialised transport systems helps to improve patient safety and the efficiency of clinical outcomes.

Training, research and care coordination

Another key topic discussed was the importance of strengthening national registries, outcome auditing and specialised ECMO training programmes. Collaboration between hospitals, scientific societies and healthcare authorities is considered essential for consolidating this advanced therapy.

Spain has highly qualified professionals in intensive care. The current challenge lies in improving organisational coordination in order to guarantee equal access and maintain high standards of quality in the management of critically ill patients.

Source: Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC)

Technological innovation and advanced organ preservation

One of the key factors behind this leadership is the adoption and widespread use of organ preservation procedures using extracorporeal circulation devices (ECMO). This advanced technology makes it possible to maintain the viability of organs suitable for transplantation. Even in highly complex clinical situations, leading to improved clinical outcomes and expanding therapeutic options for patients.

Cardiac transplantation after circulatory death: a clinical milestone

Due to its particular technical complexity, only nine countries worldwide successfully carry out this type of procedure. In Spain, cardiac transplantation after circulatory death, performed following the donor’s cardiorespiratory arrest, now accounts for 35% of all heart transplants. This figure reflects the high level of clinical and technological development of the Spanish transplant system.

A strong and coordinated healthcare system

In addition to heart transplantation, kidney, liver, lung and other specialised transplants have contributed to maintaining exceptional donation and transplantation figures. All of this is the result of a robust, well-coordinated healthcare system with a long-standing record of excellence in this field.

Organisational model, solidarity and innovation

The combination of an efficient organisational model, a strong culture of solidarity and technological advances such as ECMO systems has enabled Spain not only to maintain. Also to continue strengthening its global leadership in organ transplantation, setting the benchmark for advanced medicine and healthcare innovation.

This event will bring together interventional cardiologists from around the world to share experiences, knowledge, and the latest innovations in structural heart interventions. With 7 international speakers, 6 live clinical cases over 2 days of intensive practical training, the event aims to provide an advanced learning tool for professionals already experienced in structural therapies.

At Biogen Diagnóstica, we believe that innovation and specialised training are essential to advancing cardiovascular healthcare. Supporting initiatives like this reflects our commitment to medical progress, clinical excellence, and continuous improvement in interventional cardiology procedures.